Slide 1: Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin
Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin Lan Huang, Ph.D. Chairman, CEO & Co-Founder Feb. 11, 2026 #IO360Summit
Slide 2: Disclaimer
Disclaimer • This presentation has been prepared for informational purposes only. No money or other consideration is being solicited, and if sent in response, will not be accepted. This presentation shall not constitute an offer to sell, or the solicitation of an offer to buy, any securities, nor sh
Slide 3: Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors (ICI)
Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors (ICI) Immune Checkpoint Inhibitors (ICIs, PD-1/L1 Inhibitors) Have Transformed Cancer Care • Approved in 20+ cancer types • Have redefined first-line treatment in NSCLC and other solid tumors ➢ 60% “Acquired Resistance” to ICI • >60% p
Slide 4: Plinabulin: Unique Dual Mechanism with Immune and Safety Benefits
Plinabulin: Unique Dual Mechanism with Immune and Safety Benefits • Reversible tubulin binder – distinct from taxanes, vincas, or colchicine; does not disrupt microtubule dynamics • Immune modulation – induces dendritic cell maturation and primes T cells by activating GEF-H1 • Neutropenia mitigation
Slide 5: Plinabulin Monohydrate is a Brain-Penetrant, Unique Tubulin Depolymerizing Agent
Plinabulin Monohydrate is a Brain-Penetrant, Unique Tubulin Depolymerizing Agent which induces “Dendritic Cell or DC Maturation via GEF-H1 release” Plinabulin Monohydrate is a unique tubulin binder1 Plinabulin release GEF-H1 from microtubule, activates In WT DC cells, plinabulin can induce DC matura
Slide 6: Plinabulin's DC Maturation MoA has the Potential to Mitigate Acquired Resistance
Plinabulin’s DC Maturation MoA has the Potential to Mitigate Acquired Resistance to PD-1/L1 Inhibitors • Plinabulin MoA DC maturation: Dendritic cells (DCs) are the most potent antigen-presenting cells and can prime T cell function to strengthening the cancer- immunity cycle. • Synergistic anti-canc
Slide 7: Plinabulin Differentiated Profile
Plinabulin Differentiated Profile Mechanism Supported | Clinically Validated | Favorable Safety | Scalable Opportunity Dual Mechanism Superior Safety Profile 1 6 Significantly Lower Neutropenia and Binds Tubulin & Matures Dendritic Cells (vs. standard mitotic arrest) Bone Marrow Toxicity Microenviro
Slide 8: Post-ICI NSCLC: A Large, Growing and Unmet Clinical Challenge
Post-ICI NSCLC: A Large, Growing and Unmet Clinical Challenge • Limited treatment options after PD-1/L1 inhibitor progression • Chemotherapy remains the main option, with poor outcome and high toxicity • Urgent need for differentiated therapy with immune re-sensitization
Slide 9: Docetaxel Remains a Global Standard of Care in Post-ICI NSCLC
Docetaxel Remains a Global Standard of Care (SOC) in Post-ICI NSCLC, EGFR WT, Despite Limited Benefit and Substantial Toxicity Industry-wide Phase 3 Trials Summary Current Standard of Care 11 Phase 3 Studies: no OS Benefit vs. Docetaxel Docetaxel Overview • 7 global trials including ADCs and anti-PD
Slide 10: Dublin-3: Plinabulin and Docetaxel vs. Docetaxel in a Global Phase 3 Study
Dublin-3: “Plinabulin and Docetaxel” vs. Docetaxel in a Global Phase 3 Study with Stage IIIb/IV NSCLC EGFR WT Patients Docetaxel + Plinabulin vs. Docetaxel + Placebo in Patients with EGFR Wild-Type NSCLC Study Plan Primary endpoint Secondary endpoints • ORR, PFS • DoR • Global, randomized, single-bl
Slide 11: Plinabulin + Docetaxel Met Primary Endpoint of OS and Secondary Endpoints
Plinabulin + Docetaxel vs. Docetaxel (n=559) Met its Primary Endpoint of OS and Secondary Endpoints of PFS, ORR, and Grade 4 Neutropenia Reduction Plinabulin Significantly Reduced Plinabulin and Docetaxel Showed Significant Grade 4 neutropenia of Docetaxel Improvement in Long-term OS Rate - Double 2
Slide 12: Dublin-3: Post-hoc Analysis in Plinabulin Mechanism-Based Population
Dublin-3: Post-hoc Analysis in Plinabulin Mechanism-Based Population in 2L/3L Non-squamous EGFR WT NSCLC, Progressed on PD-1/L1 Inhibitors Non-squamous Non-squamous, Progressed on ICI mOS extension of 2.5 months mOS extension of 4.1 months (DP 11.4 vs. D 8.8 months, HR 0.72) (DP 15.8 vs. D 11.7 mont
Slide 13: Study 303 (Plinabulin + Docetaxel + PD-1) in 2L/3L Metastatic NSCLC
Study 303 (Plinabulin + Docetaxel + PD-1) in 2L/3L Metastatic NSCLC, Immediately Progressed on PD-1/L1 Inhibitors – Phase 2 IIT Study with Merck Best Change (%) in Target Lesions Primary Endpoint (n=47) Confirmed ORR（RECIST 1.1） 18.2% Secondary Endpoint Median PFS（RECIST 1.1） 7.0 months 16 months+,
Slide 14: Plinabulin + Docetaxel: Addressing Unmet Needs in 2L/3L NSCLC
Plinabulin + Docetaxel: Addressing Unmet Needs in 2L/3L NSCLC, EGFR WT, After Prior PD-1/L1 Failure with Positive Benefit/Risk Ratio Severity of Current SOC Potential Solution Unmet Need - Docetaxel - Plinabulin + Docetaxel Lack of durable response post- Strong immune re-priming, durable OS immunoth
Slide 15: Translational Biomarker: DC maturation in Responding Patients
Translational Biomarker: DC maturation in Responding Patients in Multiple Cancers who Failed ICI • Collaboration with MD Anderson • Publication: Lin et al., Med 6(10):100752 (2025)
Slide 16: Plinabulin-Responding Patients Show Early Immune Activation via DC Maturation
Plinabulin-Responding Patients Show Early Immune Activation Evidenced by Rapid DC Maturation in the Peripheral Blood CCR7, CD80 and CD83 are rapidly upregulated at cycle 1 Day 4 in responding (PR + SD) patients1 Dendritic Cell Maturation & Migration 1. Lin et al., Med 6(10):100752 (2025) 16 #IO360Su
Slide 17: Clinically Meaningful Responses in the Non-Irradiated Tumor in Hodgkin Lymphoma
Clinically Meaningful Responses in the Non-Irradiated Tumor in Hogkins Lymphoma, with Prolonged Duration of Response Patient #2: 59yoF relapsed refractory cHL diagnosed 2005. Prior treatments (16 prior lines) including ABVD x 8, ICE x 3, autoSCT with Bu/Mel, brentuximab, sirolimus and vorinostat, ni
Slide 18: First-in-Class Agent Plinabulin: Potentially Transforming Oncology Treatment
First-in-Class Agent Plinabulin: Potentially Transforming Oncology Treatment with Novel Mechanisms and Clinically Meaningful Benefits in ICI-Progressed Patients in NSCLC and Beyond + + SIMPLE SAFE DURABLE Easy to use Safety Benefit Clinical Benefit Day 1 or Day 1+ 8 use in Reduce AEs including Overa
Slide 19: Contact
Lan.huang@beyondspringpharma.com www.beyondspringpharma.com #IO360Summit